| Bioactivity | Bulaquine (CDRI 80/53) is a potent antimalarial agent which is an analogue of Primaquine (HY-12651A). Bulaquine affects multiple metabolism pathways and shows inhibition effect on Plasmodium cynomolgi infection. Bulaquine can be used for the research of malaria[1][2][3]. |
| In Vivo | Bulaquine (40 mg/kg; p.o. once) affects multiple pathways in vivo[1]. Bulaquine (1.25 mg/kg; once daily; for 7 days) shows 100% curative anti-relapse activity with a primaquine index of 0.8 for rhesus monkeys with Plasmodium cynomolgi B infection[2]. Animal Model: |
| Name | Bulaquine |
| CAS | 79781-00-3 |
| Formula | C21H27N3O3 |
| Molar Mass | 369.46 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Noel S, et al. Identification of differentially expressed genes after acute exposure to bulaquine (CDRI 80/53) in mice liver. Basic Clin Pharmacol Toxicol. 2008 Dec;103(6):522-9. [2]. Dutta GP, et al. Radical curative activity of a new 8-aminoquinoline derivative (CDRI 80/53) against Plasmodium cynomolgi B in monkeys. Am J Trop Med Hyg. 1989 Dec;41(6):635-7. [3]. Wells TN, et al. Targeting the hypnozoite reservoir of Plasmodium vivax: the hidden obstacle to malaria elimination. Trends Parasitol. 2010 Mar;26(3):145-51.Wells TN, et al. Targeting the hypnozoite reservoir of Plasmodium vivax: the hidden obstacle to malaria elimination. Trends Parasitol. 2010 Mar;26(3):145-51. |